Search

Your search keyword '"Tighe, Jane"' showing total 44 results
Start Over Author "Tighe, Jane"
44 results on '"Tighe, Jane"'

1. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Author

Russell, Nigel H., primary, Wilhelm-Benartzi, Charlotte, additional, Othman, Jad, additional, Dillon, Richard, additional, Knapper, Steven, additional, Batten, Leona M., additional, Canham, Joanna, additional, Hinson, Emily L., additional, Betteridge, Sophie, additional, Overgaard, Ulrik Malthe, additional, Gilkes, Amanda, additional, Potter, Nicola, additional, Mehta, Priyanka, additional, Kottaridis, Panagiotis, additional, Cavenagh, Jamie, additional, Hemmaway, Claire, additional, Arnold, Claire, additional, Freeman, Sylvie D., additional, Dennis, Mike, additional, Kallenbach, Maria, additional, Severinsen, Marianne, additional, Holm, Mette, additional, Maxwell Norgaard, Jan, additional, Beier Ommen, Hans, additional, Culligan, Dominic, additional, Tighe, Jane, additional, Craig, Jenny, additional, Crawley, Charles, additional, Krishnamurthy, Pramila, additional, Sadik, Walid, additional, Smith, Jeffery, additional, Dasgupta, Ranjit, additional, Berkhan, Leanne, additional, Bowett, Peter, additional, Doocey, Richard, additional, Emmett, Shannon, additional, Hawkins, Timothy, additional, Patton, Nigel, additional, Pemberton, Lucy, additional, Milne, Alison, additional, Roy, Ashok, additional, Simpson, Sylwia, additional, Cuthbert, Robert, additional, Finnegan, Damian, additional, Francis McMullin, Mary, additional, Pechey, Victoria, additional, Lovell, Richard, additional, Milligan, Donald, additional, Paneesha, Shankara, additional, Cahalin, Paul, additional, Kelsey, P., additional, Ackroyd, Sam, additional, Wiliams, Adrian, additional, Evely, Roger, additional, Marks, David, additional, Fletcher, Andrew, additional, Al-Ani, Maryam, additional, Ahmed, Khalil, additional, Lush, Richard, additional, Rye, Adam, additional, Cutting, Robert, additional, Welch, Emma, additional, Wodzinski, Mark, additional, Butler, Andrew, additional, Fernyhough, Liam, additional, Ganly, Peter, additional, Gibbons, Steve, additional, Smith, Mark, additional, Spearing, Ruth, additional, Peniket, Andy, additional, Hatcliffe, Faye, additional, Patel, Amit, additional, Lindsay, Kathrine, additional, Brearton, Gillian, additional, Tuegar, Salah, additional, Gandhi Anna Cowley, S., additional, Copplestone, Adrian, additional, Hunter, Hannah, additional, Medd, Patrick, additional, Nokes, Tim, additional, Rule, Simon, additional, Thomas, Wayne, additional, Joseph, Joe, additional, Kaul, Stuti, additional, Sorour, Youssef, additional, Chvuka, Shingi, additional, Mangos, Hilda, additional, Neylon, Annette, additional, Farrell, Katrina, additional, Edwards, Hugh, additional, Hanlon, Katharine, additional, Fail, Tom, additional, Goodrick, Margaret, additional, Heartin, Earnest, additional, Hoyle, Christine, additional, Carr, Robert, additional, Raj, Kavita, additional, Krogh Jensen, Morten, additional, Janmohamed, Riaz, additional, Kaczmarski, Richard, additional, Sugai, Taku, additional, Ademokun, Debo, additional, Chalmers, Isobel, additional, Hodson, Andrew, additional, Gomez, Cesar, additional, Sadullah, Shala, additional, Kwan, Mark, additional, Longmuir, Karyn, additional, Wilson-Morkeh, Isaac, additional, Hunter, Ann, additional, Martin, Murray, additional, Saravanamuttu, Kandeepan, additional, Sidra, Gamal, additional, Burns, Sarah, additional, Gibbs, Simon, additional, Tholouli, Eleni, additional, Aldouri, Maadh, additional, Andrews, Vivienne, additional, Eden, Ayed, additional, Dungarwalla, Moez, additional, White, Denise, additional, Laird, Jane, additional, Mitchell, Lindsey, additional, Murphy, John, additional, Paterson, Pamela, additional, Raafat, Alaeddin, additional, Mannari, Deepak, additional, Davies, Simon, additional, Austen, Belinda, additional, Allford, Sarah, additional, Kakalamudi, Sudhakar, additional, Basu, Supratik, additional, Hada, Sunil, additional, Jacob, Abraham, additional, MacWhonell, Alan, additional, McCaig, Alison, additional, Gelly, Keith, additional, Kerr, Ron, additional, Meiklejohn, David, additional, Tauro, Sudhir, additional, Lawes, Matthew, additional, Bowen, Angela, additional, Krishnamurthy, Suchitra, additional, Byrne, Jenny, additional, Dasgupta, Emma, additional, Russell, Nigel, additional, Stokley, Simone, additional, Friis, Lone, additional, Marcher, Claus, additional, Bake, Bart, additional, Chapple, Mary, additional, Moreton, Paul, additional, Omran, Asad, additional, Patil, Kavita, additional, Wright, David, additional, Jack, Fergus, additional, Maddams, Rebecca, additional, Corser, Robert, additional, Cranfield, Tanya, additional, Dignum, Helen, additional, Ganczakowski, Mary, additional, Jones, Christopher, additional, Craddock, Charles, additional, Moss, Paula, additional, Murray, Jim, additional, Craig, Joanne, additional, Forsyth, Peter, additional, Lush, Chris, additional, Wei Bjerrum, Ole, additional, Borregaard, Niels, additional, Kampmann, Peter, additional, Kjeldsen, Lars, additional, Juul Nielsen, Ove, additional, Niemann, Carsten, additional, Lykke Petersen, Soeren, additional, Udby Peter Møller, Lene, additional, Alfred, Arun, additional, Barker, Helen, additional, Went, Richard, additional, Groch, Henri, additional, Mucklow, Stuart, additional, Sampson, Rebecca, additional, Chacko, Joseph, additional, Hall, Rachel, additional, Walewska, Renata, additional, Creach, Desmond, additional, Pottinger, Bryson, additional, Addada, Juanah (Jo), additional, Hamilton, Malcolm, additional, Kerr, Paul, additional, Ngu, Loretta, additional, Rudin, Claudius, additional, Ruell, Jackie, additional, Dalley, Chris, additional, Kaur, Harpreet, additional, Reilly, John, additional, Snowden, John, additional, Ferguson, Paul, additional, Dyer, Peter, additional, Chandra, Deepak, additional, DeVos, Johannes, additional, Grey-Davies, Elisabeth, additional, Hendry, Louise, additional, Corbett, Timothy, additional, Crowe, Josephine, additional, Knechtli, Christopher, additional, Wexler, Sarah, additional, Fernandes, Savio, additional, Neilson, Jeff, additional, Houghton, John, additional, Jowitt, Simon, additional, Thomas-Dewing, Rowena, additional, Williams, Mark, additional, Zaman, Sonya, additional, Cullis, Jonathan, additional, Everington, Tamara, additional, Grand, Effie, additional, Hasan, Yasmin, additional, Murrin, Richard, additional, Wandoo, Farooq, additional, Ismail, Saad, additional, Mohite, Unmesh, additional, Sati, Hamdi, additional, Jenner, Matthew, additional, Orchard, Kim, additional, Richardson, Deborah, additional, McCloskey, Kayleigh, additional, Xu Chin, Kate, additional, Fenella Willis, Neoh, additional, Sud, Amit, additional, Gharib, Maged, additional, Nicholson, Toby, additional, Bowen, David, additional, Janes, Sarah, additional, Eagleton, Helen, additional, O'Hea, Anne-Marie, additional, Pattinson, Jonathan, additional, Hervey, Victoria, additional, Lyons, Simon, additional, Marshall, Scott, additional, Nicolle, Annette, additional, Vavyla, Maria, additional, Burgess, Jordan, additional, Somervaille, Tim, additional, Somerfield, Sven, additional, Mamat, Mohd, additional, Tomlins, Jo, additional, Salesh, Sana, additional, David, Marianna, additional, Maddox, Jamie, additional, Plews, Diane, additional, Dang, Ray, additional, Potter, Mike, additional, Ellis, Lauren, additional, Nicholson, Emma, additional, Keat, Sally, additional, Ahmed Alhassani, Thubeena M., additional, Anjum, Farahn, additional, Chatterjee, Poulami, additional, Stanchev, Atanas, additional, Peters, Jayne, additional, Lindsay-Holmes Srividhya, Sarah, additional, Chodhouri, Senthil S., additional, Eve, Heather, additional, Smith, Steve, additional, Roberts, Patrick, additional, Rymes, Nicholas, additional, Zhao New Oo, Rui, additional, Ardeshna, Kirit, additional, Blombery, Piers, additional, Khwaja, Asim, additional, Linch, David, additional, Popat, Rakesh, additional, Virchis, Andres, additional, Yong, Kwee, additional, McIntyre, Victoria, additional, Horne, Gillian, additional, Bokhari, Syed, additional, Borg, Anton, additional, Chapman, Oliver, additional, Harrison, Beth, additional, Jackson, Nicholas, additional, Jobanputra, Shailesh, additional, Narayanan, Mekkali, additional, Rose, Peter, additional, Oun, Hajer, additional, Powell, Matthew, additional, Gilles, Julie, additional, Laing, Alison, additional, Devanny, Ian, additional, Haskins, Lea, additional, Micallef-Eynaud, Paul, additional, Maclean, Peter, additional, Alvares, Caroline, additional, Kell, Jonathan, additional, Knapper, Steve, additional, Davidson, Kerri, additional, McLintock, Lorna, additional, Rogers, Stephen, additional, Williamson, Peter, additional, Corbett, Gillian, additional, Goodman, Hugh, additional, Islam, Shahid, additional, Pullon, Humphrey, additional, Johnson, Peter, additional, Roddie, P.H., additional, Maughan, Elizabeth, additional, Mills, Juliet, additional, Shafeek, Salim, additional, Narat, Santosh, additional, Aitchison, Robin, additional, Bond, Lee, additional, Munro, Laura, additional, and Edwards, David, additional

Published
2024
Full Text
View/download PDF

6. Optimizing the management of patients with spinal myeloma disease

Author

Molloy, Sean, Lai, Maggie, Pratt, Guy, Ramasamy, Karthik, Wilson, David, Quraishi, Nasir, Auger, Martin, Cumming, David, Punekar, Maqsood, Quinn, Michael, Ademonkun, Debo, Willis, Fenella, Tighe, Jane, Cook, Gordon, Stirling, Alistair, Bishop, Timothy, Williams, Cathy, Boszczyk, Bronek, Reynolds, Jeremy, Grainger, Mel, Craig, Niall, Hamilton, Alastair, Chalmers, Isobel, Ahmedzai, Sam, Selvadurai, Susanne, Low, Eric, and Kyriakou, Charalampia

Published
2015
Full Text
View/download PDF

8. Re-transplantation after bortezomib-based therapy

Author

Morris, Curly, Cook, Gordon, Streetly, Matthew, Kettle, Paul, Drake, Mary, Quinn, Michael, Cavet, Jim, Tighe, Jane, Kazmi, Majit, Ashcroft, John, Cook, Mark, Snowden, John, Olujohungbe, Ade, Marshall, Scott, Conn, Jane, Oakervee, Heather, Popat, Rakesh, and Cavenagh, Jamie

Published
2011
Full Text
View/download PDF

10. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Author

Milojkovic, Dragana, primary, Cross, Nicholas C. P., additional, Ali, Sahra, additional, Byrne, Jenny, additional, Campbell, Gavin, additional, Dignan, Fiona L., additional, Drummond, Mark, additional, Huntly, Brian, additional, Marshall, Scott, additional, McMullin, Mary Frances, additional, Neelakantan, Pratap, additional, Raghavan, Manoj, additional, Sivakumaran, Muttuswamy, additional, Tighe, Jane, additional, Wandroo, Farooq, additional, Willis, Fenella, additional, Glen, Fiona, additional, Fildes, Louise, additional, Collington, Sarah J., additional, Ryan, Jacqueline, additional, Clark, Richard E., additional, and Mead, Adam J., additional

Published
2020
Full Text
View/download PDF

12. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

Author

Gallipoli, Paolo, Stobo, Jon, Heaney, Nicholas, Nicolini, Franck E, Clark, Richard, Wilson, George, Tighe, Jane, McLintock, Lorna, Hughes, Timothy, Michor, Franziska, Paul, James, Drummond, Mark, and Holyoake, Tessa L

Subjects
therapy, chronic myeloid leukaemia, Drug Substitution, Cell Cycle, trials, Dasatinib, Fusion Proteins, bcr-abl, Drug Synergism, BCR-ABL1, Piperazines, Thiazoles, Pyrimidines, Treatment Outcome, stem cells, Pulse Therapy, Drug, Benzamides, Granulocyte Colony-Stimulating Factor, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Humans, Protein Kinase Inhibitors, Follow-Up Studies
Published
2018
Full Text
View/download PDF

16. The standard error of measurement is a more appropriate measure of quality for postgraduate medical assessments than is reliability: an analysis of MRCP(UK) examinations

Author

Dewhurst Neil G, Chis Liliana, McManus IC, Tighe Jane, and Mucklow John

Subjects
Special aspects of education, LC8-6691, Medicine
Abstract

Abstract Background Cronbach's alpha is widely used as the preferred index of reliability for medical postgraduate examinations. A value of 0.8-0.9 is seen by providers and regulators alike as an adequate demonstration of acceptable reliability for any assessment. Of the other statistical parameters, Standard Error of Measurement (SEM) is mainly seen as useful only in determining the accuracy of a pass mark. However the alpha coefficient depends both on SEM and on the ability range (standard deviation, SD) of candidates taking an exam. This study investigated the extent to which the necessarily narrower ability range in candidates taking the second of the three part MRCP(UK) diploma examinations, biases assessment of reliability and SEM. Methods a) The interrelationships of standard deviation (SD), SEM and reliability were investigated in a Monte Carlo simulation of 10,000 candidates taking a postgraduate examination. b) Reliability and SEM were studied in the MRCP(UK) Part 1 and Part 2 Written Examinations from 2002 to 2008. c) Reliability and SEM were studied in eight Specialty Certificate Examinations introduced in 2008-9. Results The Monte Carlo simulation showed, as expected, that restricting the range of an assessment only to those who had already passed it, dramatically reduced the reliability but did not affect the SEM of a simulated assessment. The analysis of the MRCP(UK) Part 1 and Part 2 written examinations showed that the MRCP(UK) Part 2 written examination had a lower reliability than the Part 1 examination, but, despite that lower reliability, the Part 2 examination also had a smaller SEM (indicating a more accurate assessment). The Specialty Certificate Examinations had small Ns, and as a result, wide variability in their reliabilities, but SEMs were comparable with MRCP(UK) Part 2. Conclusions An emphasis upon assessing the quality of assessments primarily in terms of reliability alone can produce a paradoxical and distorted picture, particularly in the situation where a narrower range of candidate ability is an inevitable consequence of being able to take a second part examination only after passing the first part examination. Reliability also shows problems when numbers of candidates in examinations are low and sampling error affects the range of candidate ability. SEM is not subject to such problems; it is therefore a better measure of the quality of an assessment and is recommended for routine use.

Published
2010
Full Text
View/download PDF

17. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.

Author

Milojkovic, Dragana, Cross, Nicholas C. P., Ali, Sahra, Byrne, Jenny, Campbell, Gavin, Dignan, Fiona L., Drummond, Mark, Huntly, Brian, Marshall, Scott, McMullin, Mary Frances, Neelakantan, Pratap, Raghavan, Manoj, Sivakumaran, Muttuswamy, Tighe, Jane, Wandroo, Farooq, Willis, Fenella, Glen, Fiona, Fildes, Louise, Collington, Sarah J., and Ryan, Jacqueline

Subjects
PROTEIN-tyrosine kinase inhibitors, CHRONIC myeloid leukemia, CARDIOVASCULAR diseases risk factors, NILOTINIB, PATIENT care
Abstract

Summary: Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real‐world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic‐phase CML who had been prescribed a first‐line TKI between 2013 and 2017, most of whom received first‐line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real‐world data revealed that molecular assessments were frequently missed, 23% of patients with ELN‐defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR‐ABL1IS ≤0·1%) and deep molecular response (DMR; BCR‐ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first‐line imatinib, and 63% and 54%, respectively, receiving a second‐generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow‐up, receiving a second‐generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. Guidelines for the use of imaging in the management of myeloma

Author

D'Sa, Shirley, Abildgaard, Niels, Tighe, Jane, Shaw, Penny, and Hall-Craggs, Margaret

Subjects
Technetium Tc 99m Sestamibi, Fluorodeoxyglucose F18, Positron-Emission Tomography, Humans, Radiopharmaceuticals, Multiple Myeloma, Tomography, X-Ray Computed, Magnetic Resonance Imaging, Whole-Body Counting, Bone and Bones
Abstract

Udgivelsesdato: 2007-Apr

Published
2007

20. Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

Author

Gallipoli, Paolo, primary, Stobo, Jon, additional, Heaney, Nicholas, additional, Nicolini, Franck E., additional, Clark, Richard, additional, Wilson, George, additional, Tighe, Jane, additional, McLintock, Lorna, additional, Hughes, Timothy, additional, Michor, Franziska, additional, Paul, James, additional, Drummond, Mark, additional, and Holyoake, Tessa L., additional

Published
2013
Full Text
View/download PDF

23. Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Author

Sayala, Hazem A., primary, Moreton, Paul, additional, Kennedy, Ben, additional, Lucas, Guy, additional, Leach, Michael, additional, Rassam, Saad M.B., additional, Haynes, Andrew, additional, Tighe, Jane, additional, Oscier, David G., additional, Fegan, Christopher, additional, Rawstron, Andy C., additional, and Hillmen, Peter, additional

Published
2007
Full Text
View/download PDF

24. A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Author

Heaney, Nicholas, primary, Drummond, Mark, additional, Kaeda, Jaspal, additional, Nicolini, Franck, additional, Clark, Richard, additional, Wilson, George, additional, Shepherd, Pat, additional, Tighe, Jane, additional, McLintock, Lorna, additional, Hughes, Timothy, additional, and Holyoake, Tessa L., additional

Published
2007
Full Text
View/download PDF

31. Leukaemia/Drosophila homology

Author

Daga, Antonio, Tighe, Jane E., and Calabi, Franco

Subjects
Acute leukemia, Promyelocytic -- Genetic aspects, Homology (Biology) -- Research, Drosophila -- Genetic aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

A human complementary DNA clone, designated AML1 because it marks a subtype of acute myeloid leukemia, is the homologue of runt, one of a group of pair-rule genes that determines morphogenesis in the fly Drosophila melanogaster. The area of homology linking the Drosophila and human polypeptide sequences extends to the conserved exon/intron boundary. Further research is needed to establish AML1's effect on human development.

Published
1992

32. Bilateral cerebellopontine angle lesions not always NF2: diagnostic pitfall.

Author

Rao, Ahsan, Lawrie, Alistair, Bodkin, Peter, Tighe, Jane, and Kamel, Mahmoud

Subjects
INTERNAL auditory meatus, TUMOR proteins, IMMUNOGLOBULIN idiotypes, INNER ear, CANCER invasiveness, CYSTS (Pathology)
Abstract

Bilateral internal auditory canal (IAC) tumours are almost exclusively associated with bilateral vestibular schwannomas, and there is very little, if anything, that can mimic this appearance. We present a very rare case of a 75-year-old gentleman who initially presented with bilateral IAC tumours and later diagnosed as an isolated primary CNS myeloma without systemic involvement. This is a very rare presentation and has important diagnostic and therapeutic implications. He was treated with a combination of lenalidomide and dexamethasone. The treatment was well tolerated but with limited response. Although rare, metastasis should be considered as a differential diagnosis of IAC lesions. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

33. Translocation Breakpoints Are Clustered on Both Chromosome 8 and Chromosome 21 in the t(8;21) of Acute Myeloid Leukemia

Author

Tighe, Jane E., Daga, Antonio, and Calabi, Franco

Abstract

The t(8;21)(q22;q22) is consistently associated with acute myeloid leukemia (AML) M2. Recent data have suggested that breakpoints on chromosome 21 are clustered within a single intron of a novel gene, AML 1,just downstream of a region of homology to the runtgene of D melanogaster.In this report, we confirm rearrangement at the same location in at least 12 of 18 patients with t(8;21). Furthermore, we have isolated recombinant clones spanning the breakpoint regions on both the der(8) and the der(21) from one patient. By using α chromosome 8 probe derived from these clones, we show that t(8;21) breakpoints are also clustered on chromosome 8.

Published
1993
Full Text
View/download PDF

34. Alternative, Out-of-Frame runt/MTG8 Transcripts Are Encoded by the Derivative(8) Chromosome in the t(8;21) of Acute Myeloid Leukemia M2

Author

Tighe, Jane E. and Calabi, Franco

Abstract

In the t(8;21) of acute myeloid leukemia (AMD M2, breakpoints are clustered on both chromosomes. The chromosome 21 breakpoint cluster region (bcr) falls within the runtlocus, in the intron immediately downstream of the exons encoding an evolutionary conserved domain (the runt box). Transcripts in which the runt box is fused in frame to a novel sequence derived from chromosome 8 (MTG8) have been previously identified and have been assumed to constitute a critical leukemogenic event. Here we show physical linkage of the chromosome 8 bcr to the MTG8locus. Unexpectedly, not only does the bcr map upstream of the most 5‘ MTG8exon found in runt/MTG8 fusion transcripts, but it also maps upstream of a further 5‘ exon. In addition, we demonstrate the presence of alternative transcripts, originating from the der(8) chromosome, in which runt is out of frame with MTG8. Thus, runt truncation per se, rather than its fusion to MTG8, may be the crucial leukemogenic event.

Published
1994
Full Text
View/download PDF

36. The Teddy Bear Book

Author

Tighe, Jane

Subjects
The Teddy Bear Book (Book) -- Book reviews, Books -- Book reviews
Published
1989

38. Things to Play With

Author

Tighe, Jane

Subjects
Things to Play With (Book) -- Book reviews, Books -- Book reviews
Published
1988

39. Thomas the Tortoise

Author

Tighe, Jane

Subjects
Thomas the Tortoise (Book) -- Book reviews, Books -- Book reviews
Published
1989

40. All My Little Ducklings

Author

Tighe, Jane

Subjects
All My Little Ducklings (Book) -- Book reviews, Books -- Book reviews
Published
1989

41. Old Bear Tales

Author

Tighe, Jane

Subjects
Old Bear Tales (Book) -- Book reviews, Books -- Book reviews
Published
1989

42. Thomas the Tortoise (Book).

Author

Tighe, Jane

Subjects
*READING interests of children, *FICTION
Abstract

Reviews the book "Thomas the Tortoise," written and illustrated by Graham Jeffery.

Published
1989

43. Old Bear Tales (Book).

Author

Tighe, Jane

Subjects
*READING interests of children, *FICTION
Abstract

Reviews the book "Old Bear Tales," written and illustrated by Jane Hissey.

Published
1989

44. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.

Author

Davidson KL, Devaney MB, Tighe JE, Rogers SY, Dunlop DJ, Mackie MJ, Thomas RV, and Johnson PR

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Cytarabine administration & dosage, Cytarabine adverse effects, Disease Progression, Doxorubicin administration & dosage, Doxorubicin adverse effects, Drug Administration Schedule, Etoposide administration & dosage, Etoposide adverse effects, Female, Granulocyte Colony-Stimulating Factor therapeutic use, Hematopoietic Stem Cell Mobilization, Humans, Ifosfamide administration & dosage, Ifosfamide adverse effects, Injections, Spinal, Lenograstim, Leucovorin administration & dosage, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin therapy, Male, Mesna administration & dosage, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Pilot Projects, Prognosis, Recombinant Proteins therapeutic use, Sepsis mortality, Treatment Outcome, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Peripheral Blood Stem Cell Transplantation, Salvage Therapy
Abstract

Background and Objectives: The prognosis in patients with primary refractory or relapsed high grade non-Hodgkin's lymphoma (NHL) is very poor--the 5-year survival being generally reported at 10%., Design and Methods: Multiple salvage regimens have been investigated and, while response rates of 50-80% have been noted in selected patients, the long-term prognosis remains poor. Following the encouraging results in high risk Burkitt's and Burkitt-like lymphoma using the CODOX-M and IVAC protocols, we performed a pilot study using a similar regimen in patients with primary refractory or relapsed high grade NHL., Results: The regimens were modified by a reduction in the intensity of intrathecal therapy. It was planned to mobilize peripheral blood stem cells following the IVAC cycle for use in subsequent autologous peripheral blood stem cell transplantation in chemosensitive patients. The initial plan was to recruit 50 patients, but the study was closed after 8 due to excessive toxicity., Interpretation and Conclusions: We conclude that the CODOX-M/IVAC regimen is too toxic for this group of patients and does not result in better response rates than those to currently available salvage regimens.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results